25. 肺炎患者のCRPの変化
全国の総合診療科の中にはCRPが大っ嫌いな人もいるので,
Articles
あまり大声で “CRP, CRP” と連呼しないように.
ちなみに僕は大好きです。
violations (webappendix pp 1–2).
For secondary outcomes, hospital mortality (web- A
250 Placebo group
appendix p 5) and rates of admission to intensive-care Dexamethasone group
units did not differ between groups (table 2). None of the
200
patients received continuous positive airway pressure or
C-reactive protein (mg/L)
non-invasive ventilation outside the intensive-care unit.
Rates of pleural effusion or empyema were less than 5% 150
経過良好の肺炎ならば,
in both groups and did not differ significantly (p=0·54;
table 2). Seven (5%) patients in both groups were
第4病日くらいにはCRPは半分に低下する 100
readmitted within 30 days of hospital discharge (table 2;
webappendix p 2).
少なくとも10日以上はCRPは上昇する経過
In the first 4 days after admission, we noted a greater
50
decline in C-reactive protein and interleukin-6 concen- 0
trations in the dexamethasone group than we did in the 0 1 2 3 4 5 6 7 10 30
Length of stay (days)
control group (figure 3). For interleukin-10, the decrease
Number at risk
was much the Online June 1, 2011
Lancet Published same between treatment groups. The Placebo group 153 141 135 131 104 84 75 53 39 112
sharp decrease we noted for interleukin-6 and
DOI:10.1016/S0140- 6736(11)60607-7 Dexamethasone group 151 130 126 121 91 70 49 33 23 115
interleukin-10 concentrations contrasts with the more
28. Table 2. Outcomes for Study Patients by Treatment Group
3-Step Critical Usual Care
Pathway Group Group Difference
Event (n = 200) (n = 201) (95% CI) a P Value b
Primary end point: LOS, median (IQR), d
Overall 3.9 (2.79 to 5.75) 6.0 (4.75 to 8.83) −2.1 (−2.7 to −1.7) Ͻ.001
IDIBELL–Hospital Universitari de Bellvitge 4.0 (2.83 to 5.75) 6.0 (4.62 to 8.88) −2.0 (−2.7 to −1.3) Ͻ.001
SCIAS–Hospital de Barcelona 3.7 (2.71 to 5.67) 6.3 (4.87 to 8.71) −2.6 (−3.2 to −1.7) Ͻ.001
Secondary end points
Length of intravenous antibiotic therapy, median (IQR), d 2.0 (2.0 to 3.0) 4.0 (2.0 to 6.0) −2.0 (−2.0 to −1.0) Ͻ.001
Adverse drug reactions, No. (%) 9 (4.5) 32 (15.9) −11.4 (−17.2 to −5.6) Ͻ.001
Phlebitis 8 (4.0) 21 (10.4) −6.4 (−11.5 to −1.4) .02
Skin eruption 0 2 (1.0) −1.0 (−2.4 to 0.4) .50
Vomiting/diarrhea 0 4 (2.0) −2.0 (−3.9 to −0.1) .12
Allergy 1 (0.5) 1 (0.5) 0 (−1.4 to 1.4) Ͼ.99
Transaminitis 0 3 (1.5) −1.5 (−3.2 to 0.2) .25
Medical complications, No. (%) 40 (20.0) 49 (24.4) −4.4 (−12.6 to 3.8) .34
Empyema 3 (1.5) 6 (3.0) −1.5 (−4.4 to 1.4) .50
Cardiac complication c 8 (4.0) 16 (8.0) −4.0 (−8.6 to 0.7) .14
Respiratory failure 15 (7.5) 8 (4.0) 3.5 (−1.0 to 8.1) .14
Acute confusion 7 (3.5) 8 (4.0) −0.5 (−4.2 to 3.2) Ͼ.99
Renal failure 7 (3.5) 8 (4.0) −0.5 (−4.2 to 3.2) Ͼ.99
Nosocomial infection 2 (1.0) 3 (1.5) −0.5 (−2.7 to 1.7) Ͼ.99
Severe hyperglycemia 3 (1.5) 9 (4.5) −3.0 (−6.3 to 0.3) .14
Shock 2 (1.0) 3 (1.5) −0.5 (−2.7 to 1.7) Ͼ.99
Subsequent hospital admission (Ͻ30 d), No. (%) d 18 (9.1) 15 (7.5) 1.6 (−3.8 to 7.1) .59
Overall case-fatality rate (Ͻ30 d), No. (%) 4 (2.0) 2 (1.0) 1.0 (−1.4 to 3.4) .45
• 3-step治療群の方が入院期間は短縮し,
Abbreviations: IDIBELL, Bellvitge Institute for Biomedical Research; IQR, interquartile range; LOS, length of hospital stay.
a Values are percentage points.
b Categorical variables were compared using the Fisher exact test and continuous variable using the Mann-Whitney test.
c Cardiac 抗生剤IV期間も短縮.of the following: heart failure (4 vs 6), arrhythmia (5 vs 11), and angina pectoris (0 vs 1).
complications included 1 or more
それに伴い薬剤による合併症も減少する.
d Excluding 4 deaths in the 3-step critical pathway group and 2 in the usual care group.
• 経口に切り替えることで膿胸や合併症が増加することも無い.
strategies of early switching to oral antibiotic have $2273 to $2373 in economic benefits.33 Therefore, our
Arch Intern Med 2012;172:922-928
mainly been evaluated in observational studies11,12,25 but finding that the application of a 3-step critical pathway
13,26,27